<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154735</url>
  </required_header>
  <id_info>
    <org_study_id>DIAD.ATTAC.2018</org_study_id>
    <nct_id>NCT04154735</nct_id>
  </id_info>
  <brief_title>Autologous Transplant Targeted Against Crohn's</brief_title>
  <acronym>ATTAC</acronym>
  <official_title>Autologous Hematopoietic Stem Cell Transplant for Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a new Phase II trial to assess the toxicity and efficacy of autologous&#xD;
      hematopoietic stem cell transplantation (HSCT) utilizing a new non-myeloablative conditioning&#xD;
      regimen in patients with high-risk Crohn's disease (CD). The regimen will include low-dose&#xD;
      immunosuppressive therapy and a targeted antibiotic for six to twelve months post-HSCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The autologous hematopoietic stem cell transplantation (HSCT) in this study utilizes a new&#xD;
      non-myeloablative conditioning regimen in patients with high-risk Crohn's disease (CD). The&#xD;
      regimen includes two types of chemotherapy (cyclophosphamide and fludarabine) as well as&#xD;
      alemtuzumab. The regimen will include low-dose immunosuppressive therapy with tacrolimus&#xD;
      (Prograf) for one year post-HSCT in attempt to prevent relapse and improve long-term&#xD;
      remission. Patients will also receive rifaximin (Xifaxan) for six months post-HSCT to target&#xD;
      abnormal intestinal microbiota that may trigger intestinal inflammation. The ability of these&#xD;
      experimental treatments to stop relapses and progression (worsening) of Crohn's disease will&#xD;
      be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Discontinued by Investigator&#xD;
  </why_stopped>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Treatment-related mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Survival of participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Change of Crohn's Disease Activity Index CDAI ≤ 150, Harvey-Bradshaw Index (HBI) ≤4, may be on immune suppressive drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission</measure>
    <time_frame>1 year, 2 years, 3 years</time_frame>
    <description>Change of Clinical, endoscopic, and histologic remission on no immune modulating drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Craig's Crohn's Severity Index</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Improvement in the severity of Crohn's Disease according to the Craig's Crohn's Severity Index (CDAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic severity scales</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Improvement on the Simple Endoscopic Score for Crohn's Disease (SES-CD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic remission on colonoscopy with biopsy</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>No evidence of disease on biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>No evidence of disease on colonoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug-free clinical remission</measure>
    <time_frame>1 year, 2 years, 3 years</time_frame>
    <description>Crohn's Disease Activity Index (CDAI ≤ 150),Harvey Bradshaw Index HBI ≤4, no immune suppressive drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Relapse is defined as Crohn's Disease Activity Index CDAI &gt;150, Harvey Bradshaw Index HBI &gt;4, and restarting or increasing immune based medication(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool markers</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Improvement in fecal calprotectin and fecal lactoferrin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life short form Survey (SF-36)</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Improvement in quality of life, measured by 36-Item Short Form Survey (SF-36) The evaluation of the results was done by attributing scores to each question, which were then transformed into a scale ranging from 0 to 100, where 0 corresponds to the worst quality of life and 100 to the best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Bowel Disease Questionnaire</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Improvement on the Inflammatory Bowel Disease Questionnaire (IBDQ) Total IBDQ score ranges from 32 to 224. A higher score indicates better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's Disease Endoscopic Index of Severity (CDEIS)</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years</time_frame>
    <description>Improvement on the Crohn's Disease Endoscopic Index of Severity (CDEIS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with fludarabine, cyclophosphamide, mesna, and alemtuzumab. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant until engraftment. Rifaximin and tacrolimus will be administered for 6 and 12 months, respectively, beginning one day before the infusion of stem cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>A chemotherapy medication commonly used in the treatment of leukemia and lymphoma</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>A medication used as chemotherapy and to suppress the immune system</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Lemtrada</other_name>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Filgrastim</other_name>
    <other_name>Granix</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Xifaxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Envarsus XR</other_name>
    <other_name>Stargraf XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years and less than age 50 years at the time of pre-transplant evaluation&#xD;
&#xD;
          2. Ability to give informed consent&#xD;
&#xD;
          3. An established clinical diagnosis of severe Crohn's Disease* that has failed therapy&#xD;
             with prednisone or budesonide (Entocort) and either a or b below:&#xD;
&#xD;
               1. At least two anti-tumor necrosis factor (TNF) drugs (e.g., infliximab (Remicade),&#xD;
                  adalimumab (Humira), or certolizumab pegol (Cimzia))&#xD;
&#xD;
               2. One anti-TNF drug as above and either vedolizumab (Entyvio) or ustekinumab&#xD;
                  (Stelara)&#xD;
&#xD;
                    -  Severe Crohn's Disease is defined as a CDAI (see Appendix A) of 250 to 400&#xD;
                       or a Craig's Crohn's Severity Index (CCSI, see Appendix B) that is &gt; 17.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled diabetes mellitus or any other illness that in the opinion of the&#xD;
             investigators would jeopardize the ability of the patient to tolerate aggressive&#xD;
             treatment&#xD;
&#xD;
          2. Prior history of malignancy (except localized basal cell or squamous cell skin cancer,&#xD;
             or carcinoma in situ of the cervix). Other malignancies for which the patient is&#xD;
             judged to be cured by local surgical therapy, such as head and neck cancer, or stage I&#xD;
             breast cancer will be considered on an individual basis&#xD;
&#xD;
          3. Positive pregnancy test, inability to pursue effective means of birth control, or&#xD;
             failure to willingly accept or comprehend irreversible sterility as a side effect of&#xD;
             therapy&#xD;
&#xD;
          4. HIV positive&#xD;
&#xD;
          5. Hepatitis B or C positive&#xD;
&#xD;
          6. Psychiatric illness or mental deficiency making compliance with treatment or informed&#xD;
             consent impossible&#xD;
&#xD;
          7. Untreated life-threatening cardiac arrhythmia on EKG or 24-hour holter or history of&#xD;
             coronary artery disease or congestive heart failure&#xD;
&#xD;
          8. Left ventricular ejection fraction (LVEF) &lt;50%&#xD;
&#xD;
          9. Forced vital capacity (FVC) &lt;60% of predicted after bronchodilator therapy (if&#xD;
             necessary) or diffusing capacity of the lungs for carbon monoxide (DLCO) hemoglobin&#xD;
             corrected &lt;60 % predicted&#xD;
&#xD;
         10. Serum creatinine &gt;2 mg/dl&#xD;
&#xD;
         11. 24-hour urine creatinine clearance &lt;90&#xD;
&#xD;
         12. Liver transaminases &gt;2x of normal limits, or bilirubin &gt;2 mg/dl unless due to Crohn's&#xD;
             Disease&#xD;
&#xD;
         13. Major hematological abnormalities such as platelet count &lt; 100,000/ul or absolute&#xD;
             neutrophil count (ANC) &lt; 1500/ul&#xD;
&#xD;
         14. Failure to collect at least 2 x10^6 cluster of differentiation 34 (CD34+) cells/kg&#xD;
&#xD;
         15. Any active infection&#xD;
&#xD;
         16. Known hypersensitivity to mouse, rabbit, or E. coli derived proteins&#xD;
&#xD;
         17. Short Bowel Syndrome defined as intestinal dysfunction with the presence of&#xD;
             significant malabsorption of both macronutrients and micronutrients or when&#xD;
             gastrointestinal function is inadequate to maintain nutrient and hydration status&#xD;
             without intravenous or enteral supplementation.&#xD;
&#xD;
         18. History of anorexia nervosa (serum albumin ≤ 20 g/L, body mass index ≤ 18)&#xD;
&#xD;
         19. Patients presenting with intestinal perforation or toxic megacolon or a problem that&#xD;
             will require urgent surgery. The presence of intestinal stomas, strictures, or&#xD;
             fistulae does not exclude the patient from study.&#xD;
&#xD;
         20. Unable or unwilling to stop using and/or smoking tobacco products&#xD;
&#xD;
         21. Abnormal peripheral blood cytogenetics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>Division Chief, Immunotherapy and Autoimmune Diseases</investigator_title>
  </responsible_party>
  <keyword>Autologous Stem Cell Transplantation</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

